

Screening for Hepatitis B Virus Infection in Pregnancy: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement

[U.S. Preventive Services Task Force](#)

Abstract

Description:

Reaffirmation of the 2004 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for hepatitis B virus hepatitis B virus infection in pregnancy.

Methods:

The USPSTF performed a brief literature update, including a search for new and substantial evidence on the benefits and harms of screening pregnant women for hepatitis B virus infection.

Finding:

The net benefit of screening continues to be well established.

Recommendation:

Screen for hepatitis B virus infection in pregnant women at their first prenatal visit. (Grade A recommendation.)

The U.S. Preventive Services Task Force (USPSTF) makes recommendations about preventive care services for patients without recognized signs or symptoms of the target condition.



It bases its recommendations on a systematic review of the evidence of the benefits and harms and an assessment of the net benefit of the service.

The USPSTF recognizes that clinical or policy decisions involve more considerations than this body of evidence alone. Clinicians and policymakers should understand the evidence but individualize decision making to the specific patient or situation.

Summary of Recommendation and Evidence

The USPSTF recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit. (This is a grade A recommendation.)

See the [Figure](#) for a summary of the recommendation and suggestions for clinical practice.

Annals of Internal Medicine  

**SCREENING FOR HEPATITIS B VIRUS (HBV) INFECTION IN PREGNANCY
CLINICAL SUMMARY OF U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATION**

Population	All Pregnant Women
Recommendation	Screen at the first prenatal visit
	Grade: A
Screening Tests	Serologic identification of hepatitis B surface antigen (HBsAg). Reported sensitivity and specificity are greater than 98%.
Timing of Screening	Order HBsAg testing at the first prenatal visit. Rescreen women with unknown HBsAg status or new or continuing risk factors at admission to hospital, birth center, or other delivery setting.
Interventions	Administer hepatitis B vaccine and hepatitis B immune globulin to HBV-exposed infants within 12 hours of birth. Refer women who test positive for counseling and medical management. Counseling should include information about how to prevent transmission to sexual partners and household contacts. Reassure patients that breastfeeding is safe for infants who receive appropriate prophylaxis.
Implementation	Establish systems for timely transfer of maternal HBsAg test results to the labor and delivery and newborn medical records.
Relevant USPSTF Recommendations	USPSTF recommendations on the screening of pregnant women for other infections, including asymptomatic bacteriuria, bacterial vaginosis, chlamydia, HIV, and syphilis, can be found at www.preventiveservices.ahrq.gov .

For a summary of the evidence systematically reviewed in making these recommendations, the full recommendation statement, and supporting documents, please go to www.preventiveservices.ahrq.gov.

Figure. Screening for hepatitis B virus infection in pregnancy: clinical summary of U.S. Preventive Services Task Force Recommendation.

[Table 1](#) describes the USPSTF grades, and [Table 2](#) describes the USPSTF classification of levels of certainty about net benefit. Both are also available at www.annals.org.

Table 1. What the USPSTF Grades Mean and Suggestions for Practice

Table 1. What the USPSTF Grades Mean and Suggestions for Practice

Grade	Definition	Suggestions for Practice
A	The USPSTF recommends the service. There is high certainty that the net benefit is substantial.	Offer/provide this service.
B	The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.	Offer/provide this service.
C	The USPSTF recommends against routinely providing the service. There may be considerations that support providing the service in an individual patient. There is moderate or high certainty that the net benefit is small.	Offer/provide this service only if other considerations support offering or providing the service in an individual patient.
D	The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.	Discourage the use of this service.
I statement	The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.	Read the clinical considerations section of the USPSTF Recommendation Statement. If the service is offered, patients should understand the uncertainty about the balance of benefits and harms.

USPSTF = U.S. Preventive Services Task Force.

Table 2. U.S. Preventive Services Task Force Levels of Certainty Regarding Net Benefit

Level of Certainty*	Description
High	The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary care populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore unlikely to be strongly affected by the results of future studies.
Moderate	The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate is constrained by such factors as: the number, size, or quality of individual studies inconsistency of findings across individual studies limited generalizability of findings to routine primary care practice lack of coherence in the chain of evidence. As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large enough to alter the conclusion.
Low	The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of: the limited number or size of studies important flaws in study design or methods inconsistency of findings across individual studies gaps in the chain of evidence findings that are not generalizable to routine primary care practice a lack of information on important health outcomes. More information may allow an estimation of effects on health outcomes.

*The U.S. Preventive Services Task Force (USPSTF) defines certainty as “likelihood that the USPSTF assessment of the net benefit of a preventive service is correct.” The net benefit is defined as benefit minus harm of the preventive service as implemented in a general primary care population. The USPSTF assigns a certainty level based on the nature of the overall evidence available to assess the net benefit of a preventive service.

Rationale

Importance

An estimated 24 000 infants are born each year to women in the United States who are infected with HBV. Between 30% and 40% of all chronic HBV infections result from perinatal transmission. Chronic HBV infections increase long-term morbidity and mortality by predisposing infected persons to cirrhosis of the liver and liver cancer.

Detection

The principal screening test for detecting maternal HBV infection is the serologic identification of hepatitis B surface antigen (HBsAg). Immunoassays for detecting HBsAg have a reported sensitivity and specificity greater than 98%.

Benefits of Detection and Early Intervention

The USPSTF found convincing evidence that universal prenatal screening for HBV infection substantially reduces perinatal transmission of HBV and the subsequent development of chronic HBV infection. The current practice of vaccinating all infants against HBV infection and providing postexposure prophylaxis with hepatitis B immune globulin administered at birth to infants of mothers infected with HBV substantially reduces the risk for acquiring HBV infection.

Harms of Detection and Early Intervention

The USPSTF found no published studies that describe harms of screening for HBV infection in pregnant women. The USPSTF concluded that the potential harms of screening are no greater than small.

USPSTF Assessment

The USPSTF concludes that there is high certainty that the net benefit of screening pregnant women for HBV infection is substantial.

Clinical Considerations

Patient Population Under Consideration

This recommendation applies to all pregnant women.

Screening Tests

Screening for HBV infection by testing for HBsAg should be performed in each pregnancy, regardless of previous hepatitis B vaccination or previous negative HBsAg test results.

Timing of Screening

A test for HBsAg should be ordered at the first prenatal visit with other recommended screening tests. At the time of admission to a hospital, birth center, or other delivery setting, women with unknown HBsAg status or with new or continuing risk factors for HBV infection (such as injection drug use or evaluation or treatment for a sexually transmitted disease) should receive screening.

Treatment

Infants born to HBV-infected mothers should receive hepatitis B vaccine and hepatitis B immune globulin within 12 hours of birth. Infants born to mothers with unknown HBsAg status should receive hepatitis B vaccine within 12 hours of birth, followed by hepatitis B immune globulin as soon as possible (but not later than 7 days after birth) if the mother tests positive for HBsAg.

Pregnant women who test positive for HBsAg should be referred to an appropriate case-management program and should be provided with or referred for counseling and medical management of HBV infection. Counseling should include information about prevention of

HBV transmission to sexual partners and household contacts and reassurance regarding the safety of breastfeeding in infants who receive appropriate prophylaxis.

Other Considerations

Implementation

Screening for HBV infection in pregnant women is necessary but not sufficient to prevent disease transmission to newborns. To realize the maximum benefit from screening, primary care clinicians and delivery settings must establish effective systems for the accurate and timely transfer of maternal HBsAg test results to the labor, delivery, and newborn medical records.

Research Needs/Gaps

Research is needed to assess the effect of long-standing universal childhood hepatitis B vaccination on the magnitude of benefit of screening for HBV infection in U.S.-born pregnant women. Research is also needed to determine the net health benefit to the mother and infant of treating pregnant women whose chronic HBV infections are identified by prenatal screening.

Discussion

In 2004, the USPSTF reviewed the evidence for screening for HBV infection in pregnant women and found that the benefits of screening substantially outweighed the harms (1). In 2008, the USPSTF performed a brief literature update (2) and determined that the net benefit of screening pregnant women for hepatitis B continues to be well established. This update included a search for new and substantial evidence on the benefits and harms of screening. The USPSTF found no new substantial evidence that could change its recommendation and, therefore, reaffirms its recommendation to screen pregnant women for hepatitis B at their first prenatal visit. The previous recommendation statement (3) and evidence review, as well as the current summary of the updated literature search, can be found at www.preventiveservices.ahrq.gov.

Recommendations of Others

The American Academy of Family Physicians strongly recommends screening for HBV infection in pregnant women at their first prenatal visit (4). This recommendation is available at www.aafp.org/online/en/home/clinical/exam.html.

The American College of Obstetricians and Gynecologists recommends routine screening of all pregnant women with HBsAg (5).

The American Academy of Pediatrics recommends HBsAg testing for all pregnant adolescents “at the time a pregnancy is discovered, regardless of hepatitis B immunization history and previous results of tests for HBsAg and antibody to HBsAg” (6). This

recommendation is available
at aapredbook.aappublications.org/cgi/content/full/2006/1/2.9.2.

The Centers for Disease Control and Prevention recommends that all pregnant women be tested routinely for HBsAg during an early prenatal visit (for example, first trimester) in each pregnancy, even if they have been previously vaccinated or tested (7). This recommendation is available
at www.cdc.gov/mmwr/preview/mmwrhtml/rr5416a1.htm?s_cid=rr5416a1_e.

Appendix: U.S. Preventive Services Task Force

Members of the U.S. Preventive Services Task Force† are Ned Calonge, MD, MPH, *Chair* (Colorado Department of Public Health and Environment, Denver, Colorado); Diana B. Petitti, MD, MPH, *Vice-Chair* (Arizona State University, Phoenix, Arizona); Thomas G. DeWitt, MD (Children's Hospital Medical Center, Cincinnati, Ohio); Allen J. Dietrich, MD (Dartmouth Medical School, Hanover, New Hampshire); Kimberly D. Gregory, MD, MPH (Cedars-Sinai Medical Center, Los Angeles, California); David Grossman, MD (Group Health Cooperative, Seattle, Washington); George Isham, MD, MS (HealthPartners, Minneapolis, Minnesota); Michael L. LeFevre, MD, MSPH (University of Missouri School of Medicine, Columbia, Missouri); Rosanne M. Leipzig, MD, PhD (Mount Sinai School of Medicine, New York, New York); Lucy N. Marion, PhD, RN (School of Nursing, Medical College of Georgia, Augusta, Georgia); Bernadette Melnyk, PhD, RN (Arizona State University College of Nursing & Healthcare Innovation, Phoenix, Arizona); Virginia A. Moyer, MD, MPH (Baylor College of Medicine, Houston, Texas); Judith K. Ockene, PhD (University of Massachusetts Medical School, Worcester, Massachusetts); George F. Sawaya, MD (University of California, San Francisco, San Francisco, California); J. Sanford Schwartz, MD (University of Pennsylvania Medical School and the Wharton School, Philadelphia, Pennsylvania); and Timothy Wilt, MD, MPH (University of Minnesota Department of Medicine and Minneapolis Veteran Affairs Medical Center, Minneapolis, Minnesota).

† Members of the Task Force at the time this recommendation was finalized. For a list of current Task Force members, go to www.ahrq.gov/clinic/uspstfab.htm.

Comments

1 Comment

[SIGN IN TO SUBMIT A COMMENT](#)

Alain Braillon University Hospital. Amiens. France 22 June 2009

A simple guideline for Clinical Practice Guideline updating.

A simple guideline for Clinical Practice Guideline updating.

Clinical Practice Guideline (CPG) are regarded as a solution to get effective health care (1). Their obsolescence is a frequent and serious concern which preclude physicians to adopt

evidence based medicine (2). Therefore, updating can be applauded. However a mandatory pre-request is forgotten: the assessment of the CPG's implementation!

The U.S. Preventive Services Task Force update cited four other organizations which issued the same guideline for screening for AgHBs during pregnancy (3). None published data assessing the adherence to this CPG. In France, the 1992 mandatory screening for AgHBs during pregnancy was reaffirmed in 2004. Again, no one has concern for its evaluation. We just published the first data which showed that compliance must be improved (4). Ongoing evaluation of the CPG for the treatment of infants born to HBV-infected mothers too shows poor conformity to the recommended processes and non relevant indications.

When, issuing a GPG one must plan measuring the adherence to it. Accordingly, funding must be foreseen. Recommendation and reaffirmation are not sufficient to obtain quality. Evaluation of practice performance, plus corrective actions when needed, are necessary and essential.

References

1 Haynes B, Haines A. Barriers and bridges to evidence based clinical practice. *BMJ*. 1998;317:273-6.

2 Braillon A, Gignon M, Dubois G. G-I-N must adopt the WHISKY statement. *Qual Saf Health Care*. 2005;14:391.

3 U.S. Preventive Services Task Force. Screening for hepatitis B virus Infection in pregnancy: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med*. 2009;150:869-73.

4 Braillon A, Nguyen-Khac E. Pregnancy and hepatitis B in Europe. *Liver Int*. 2009; Jun 6 (In press).

Funding: this study had no explicit funding.

Ethical approval: Not needed.

Conflict of Interest:

None declared